Gilead Sciences, Inc.

Doris T Tang

Kin Shing Yang

Chandrasekar Venkataramani

Barton W Phillips

Anna Zagorska

Julie Farand

Peiyuan Wang

Zhimin Du

Gregory Notte

Brian P Bestvater

Richard L Mackman

Dustin S Siegel

Scott D Schroeder

Hon Chung Hui

Joshua A Kaplan

Michael R Mish

Hai Yang

Mark J Bartlett

Gregory F Chin

Nathan D Shapiro

Michael O Clarke

Jennifer Leigh Cosman

Bindu Goyal

Deeba Ensan

Stephen Ho

The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH).

LPA receptor antagonists and uses thereof

The present disclosure provides pyrimidine dione compounds of Formula I

CD73 compounds

Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof

The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD), or chronic kidney disease (CKD).

The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non alcoholic steatohepatitis (NASH).

Growing community of inventors

Burlingame, CA, United States of America

Doris T Tang